No a Judge Did Not Rule Abortion Pills are Safe

Late last week, U.S. District Judge Robert S. Ballou ruled that the Food and Drug Administration failed to justify some of its remaining safety requirements for mifepristone, the first drug used in the chemical abortion regimen.

The Center for Reproductive Rights quickly declared the ruling a “win for science.” It claimed that mifepristone is “exceedingly safe” and that the remaining safeguards exist for political reasons.

That is not what the court decided.

Judge Ballou did not declare mifepristone risk-free. He did not order the FDA to remove every restriction. His ruling found that the agency had not adequately explained why it retained certain requirements in 2023, including certification for prescribers and pharmacies and a patient agreement form. He sent the matter back to the FDA for further consideration.

Click here to sign up for pro-life news alerts from LifeNews.com

In plain English, the court told the FDA to explain itself more fully. That is far different from proving that the restrictions lack a medical purpose.

The decision arose under the Administrative Procedure Act, which requires federal agencies to support their decisions with clear reasoning. Courts can order agencies to reconsider decisions that lack adequate explanation, but they do not settle scientific disputes simply by doing so.

This ruling also represents only one decision in a much larger legal battle. Other federal courts have upheld the FDA’s current mifepristone rules. In 2024, the Supreme Court dismissed a separate challenge because the plaintiffs lacked standing. The Court did not decide whether the FDA acted lawfully or whether its scientific conclusions were correct.

Calling the Virginia ruling a final scientific judgment is advocacy dressed up as analysis.

The claim that mifepristone is “exceedingly safe” also deserves scrutiny. A 2023 population-based study of women in Ontario, published in the Annals of Internal Medicine, found that 10.3 percent of women who underwent chemical abortions visited an emergency department afterward.

The FDA’s own post-marketing reports have documented deaths associated with mifepristone use, including cases involving sepsis and complications from ectopic pregnancies. Determining causation can prove difficult, but that does not make the reports irrelevant.

Other analyses have identified serious complications such as hemorrhage, infection, incomplete abortion, and the need for emergency surgery. The full extent of these problems remains difficult to measure because the FDA no longer requires abortion providers to report most nonfatal complications.

Incomplete abortions are particularly concerning. Some women require additional medication or surgery after the regimen fails to remove all pregnancy tissue. Mail-order distribution and telemedicine can make it harder to confirm gestational age, diagnose ectopic pregnancy, or ensure that women receive timely follow-up care.

The FDA’s statement that mifepristone is “safe and effective” under approved conditions does not prove that every safeguard is unnecessary. Federal regulators routinely impose special controls on drugs with known serious risks. A drug can meet the FDA’s approval standard while still requiring careful prescribing, monitoring, and reporting.

There is also a deeper truth that abortion advocates refuse to acknowledge. Mifepristone works by blocking progesterone, the hormone that sustains pregnancy. Misoprostol then causes contractions to expel the developing child.

The regimen does not merely carry a risk of ending a human life. Ending that life is its intended purpose.

No discussion of “safety” can honestly ignore the unborn child. A successful chemical abortion always ends in death for that child. The Center for Reproductive Rights focuses exclusively on maternal complication statistics because recognizing the second human being would expose the moral emptiness of its argument.

Nor can abortion advocates divide this debate neatly between “science” and “politics.” Decisions about abortion drugs involve medicine, law, federal authority, maternal health, and the government’s responsibility to protect human life. Those questions have surrounded mifepristone since the FDA first approved it in 2000 and continued as the agency expanded its use and removed safeguards.

The Virginia decision is a procedural setback for the Trump administration, not a scientific or moral settlement. Judge Ballou ordered the agency to provide better explanations. He did not prove that mifepristone is harmless, that existing safeguards lack value, or that opposition to chemical abortion rests on politics rather than evidence.

The victory statements cannot conceal the truth. Mifepristone presents real dangers to women, and every successful use deliberately ends the life of an unborn child. Any honest examination of the drug must begin there.

LifeNews.com Note: Raimundo Rojas is the Outreach Director for the National Right to Life Committee. He is a former president of Florida Right to Life and has presented the pro-life message to millions in Spanish-language media outlets. He represents NRLC at the United Nations as an NGO. Rojas was born in Santiago de las Vegas, Havana, Cuba and he and his family escaped to the United States in 1968.